(NasdaqGM:REFI), CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the quarter ended September 30, 2025. Peter Sack, Co-Chief Executive Officer, noted, “Our loan portfolio and earnings performance this quarter continue to […]
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Woof Gang Bakery & Grooming (“Woof Gang” or “the Company”), the neighborhood pet grooming and treat boutique, is proud to announce the launch of its first-ever mobile app, delivering a faster, smarter, and more connected experience for pet parents and store owners nationwide. The new app is the
(NASDAQ:CCBG), TALLAHASSEE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Capital City Bank today announced that Alicia Williams-Ronan has assumed the role of chief retail officer. She succeeds Randy Lashua, who will retire on December 31 after 20 years of service. In this role, Williams-Ronan will oversee strategy and direct management for all retail sales, service
(Neo:VRNO.NE),(OTC US:VRNOF),(OtherOTC:VRNOF), CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the completion of its previously announced plan to redomicile Verano Holdings Corp. from British Columbia, Canada, to the State of Nevada. The redomicile was approved by the
(NasdaqGM:KYMR), Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 KT-579 (IRF5) IND-enabling studies completed, with Phase 1 clinical
(NasdaqGM:MAZE), SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November
(NASDAQ:BEAM), Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Presentation at American Society of Hematology (ASH)
The bipartisan group of state legislators and executive officers will focus on developing responsible AI policies while advancing AI-powered economic growth opportunities across the heartland Today, Heartland Forward announced the launch of the Heartland AI Caucus, a bipartisan group of state leaders committed to creating and accelerating smart AI policy and actionable outcomes to advance
(NASDAQ:HOWL), – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to
(TSX:SJ), MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). Open to: Investors, analysts and all interested parties Date: Wednesday November 5, 2025 Time: 10:00 AM Eastern Standard Time (EST) Live Webcast: https://meetings.lumiconnect.com/400-700-172-835 Call: (+1) 800 990 2777 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH